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Abstract: Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibitor, which has
been widely utilized throughout the cancer research field. SAHA-induced radiosensitization in
normal human fibroblasts AG1522 and lung carcinoma cells A549 were evaluated with a combination
of γ-rays, proton, and carbon ion exposure. Growth delay was observed in both cell lines during
SAHA treatment; 2 µM SAHA treatment decreased clonogenicity and induced cell cycle block in G1
phase but 0.2 µM SAHA treatment did not show either of them. Low LET (Linear Energy Transfer)
irradiated A549 cells showed radiosensitization effects on cell killing in cycling and G1 phase with 0.2
or 2 µM SAHA pretreatment. In contrast, minimal sensitization was observed in normal human cells
after low and high LET radiation exposure. The potentially lethal damage repair was not affected by
SAHA treatment. SAHA treatment reduced the rate of γ-H2AX foci disappearance and suppressed
RAD51 and RPA (Replication Protein A) focus formation. Suppression of DNA double strand break
repair by SAHA did not result in the differences of SAHA-induced radiosensitization between human
cancer cells and normal cells. In conclusion, our results suggest SAHA treatment will sensitize cancer
cells to low and high LET radiation with minimum effects to normal cells.
Keywords: proton; carbon ions; SAHA
1. Introduction
Radiosensitizers can be beneficial for radiation therapy via increasing cell killing [1]. However,
radiosensitizers are still under trial and testing. Therefore, it is important to search clinically
approved anti-cancer drugs for novel radiosensitizing effects to avoid complications during drug trials.
Second-generation histone deacetylase inhibitor (HDACi), suberovlanilide hydroxamic acid (SAHA;
commercial name, vorinostat) is a USA Food and Drug Administration (FDA)-approved drug for
cutaneous T cell lymphoma treatment [2,3]. In vitro and in vivo studies suggested that HDACi could be
used to treat many types of cancers [4]. HDACi has portrayed a broad spectrum of epigenetic activities
by the accumulation of acetylated histones and acetylated non-histone proteins. Several studies
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have shown HDACi sensitizes cancer stem-like cells to damaging agents [5–7]. Recent publications
have reported not only anti-tumor effects but also radiosensitization effects of SAHA through DNA
double strand break repair inhibition [8–10]. One pathway identified in these publications was the
homologous recombination repair pathway [11–14], and another pathway was non-homologous end
joining repair through Ku70 and 86 [15,16]. These DNA repair inhibitory effects by HDACi were
combined with photon ionizing radiation and chemotherapeutic agents, and showed synergistic effects
for cell killing. However, a combination of HDACi with particle radiation, including proton and
carbon ion, are still limited [17–20].
As an anti-tumor drug, SAHA has selective cytotoxicity in transformed normal cells and cancer
cells [7]. Cells with a mutation in p53 are sensitive to SAHA. In addition, HDACi may have a protective
role in normal cells by suppressing the oncogenes, radiation-induced inflammatory cytokines, and
stimulating the proliferation of stem cells [21,22]. Other factors such as extended phosphorylation of
H2AX may be associated with this selective toxicity and radiosensitization [23,24]. Since cytotoxicity
and radiation sensitivity often share the same mechanisms, SAHA’s radiosensitization effect may be
also selective to cancer cells. One of the reasons why radiosensitizers are still in testing or trial is that
drugs often sensitize both normal and cancer cells. For example, BrdU is a classical radiosensitizer
for highly proliferative cells such as cancer cells [1]. Caffeine which is commonly available in various
beverages can suppress cell cycle checkpoint and sensitize cells to radiation [25]. Neither of the latter
chemicals portray clinical relevance, due to their high toxicity and non-selective sensitization effects.
Therefore, the potentially selective radiosensitization effect of SAHA is useful in a clinical setting.
One of the advantages of hadron radiation therapy is an excellent dose distribution within the target
tumor volume. Late effects of proton and carbon ion therapy has been shown to be superior to that of
intensity modulated radiation therapy [26]. In radiotherapy, reducing the therapy dose is of particular
importance. Therefore, SAHA might be a suitable combined modality for hadron radiation therapy.
In this paper, we hypothesize that the anti-tumor drug SAHA selectively sensitizes cancer cells to
DNA damage from both photon radiation and hadron radiation. We have investigated the selective
sensitization with SAHA treatment in cancer cells versus normal cells. Furthermore, we explored the
DNA damage response and repair to understand mechanisms of selective radiosensitization by SAHA.
2. Results
2.1. Cellular Toxicity and Cell Cycle Distribution from SAHA Treatment
Cell doubling time of AG1522 normal human fibroblast cells was approximately 28 h. That of A549
human lung carcinoma was approximately 16 h (Figure 1A). Three-day SAHA continuous treatment
reduced cellular growth rate in both normal and cancer cell lines (Figure 1B). Log growing cells were
exposed to different concentrations of SAHA (0.2–4 µM). Dose dependent cell growth inhibition was
observed for both cell lines in the tested range, 0.2 to 4 µM (Figure 1B). Also, 2 µM and 4 µM SAHA
treatment showed significant growth inhibition at 3 days compared to control (p < 0.05).
In order to determine whether SAHA-reduced growth was associated with cell death, a clonogenic
survival test was carried out after 24 h SAHA treatment. Plating efficiency without SAHA treatment of
AG1522 was 25% and A549 was 55% in our experimental conditions. Clonogenic survival showed
a slight reduction of clonogenicity with the high concentration (2 µM) treated AG1522 was 20% and
A549 was 45% and no toxic effects were seen at a low concentration (0.2 µM) treatment (Figure 1C).
However, no statistical significance for the different conditions was observed in both AG1522 and
A549 cells (ANOVA (Analysis of Variance) p = 0.115 and p = 0.345, respectively).
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Figure 1. Suberoylanilide hydroxamic acid (SAHA)’s effects to human normal fibroblast and cancer 
cell culture conditions. (A) Cellular doubling times of AG1522 and A549; (B) Cellular toxicity 
evaluated by cell growth for three days in the presence SAHA; (C) Cellular toxicity evaluated by 
clonogenic ability as plating efficiency; (D) Flow cytometry profiles after SAHA treatment for 24 h; 
and (E) Cell cycle distribution after 24 h SAHA treatment. Error bars indicate standard error of the 
means. * marks mean statistically significant differences compared to control (p < 0.05). All 
experiments were carried out at least three times independently. 
Cell cycle distribution after 24 h 2 μM SAHA treatment presented cell cycle arrest for both 
normal cells and cancer cells in G1 phase (Figure 1D,E). G1 phase population increased from 50–60% 
to more than 80%, with statistical significance (p < 0.05). S phase population was decreased from 30% 
to 5%, with statistical significance (p < 0.05). G2/M phase population remained the same. Therefore, 
the slower cell division by SAHA treatment may arise from temporary cell division arrest, such as 
activation of the cell cycle checkpoints but not permanent senescence. 
2.2. Radiosensitization of Exponentially Growing Cancer Cells Exposed to γ-Rays, Protons and Clinical Grade 
Carbon Ions  
Two concentrations of SAHA (0.2 and 2 μM) were used for radiosensitization tests for the 
exponentially growing A549 cells. It was found that 2 μM of SAHA pretreatment resulted in 
statistically significant radiosensitization for γ-rays, proton SOBP (Spread out Bragg Peak), and 
carbon ion SOBP (p < 0.05). In contrast, 0.2 μM of SAHA pretreatment induced statistically 
significant radiosensitization with proton SOBP and carbon ion SOBP (p < 0.05) but not γ-rays 
(Figure 2A). Although low concentrations of SAHA did not show any cell cycle differences from 
control (Figure 1D), it showed similar sensitization effects to protons and carbon ion exposure for 
A549 lung cancer cell line when compared to high concentrations of SAHA. 
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Figure 1. S be oyla ilide hydroxamic aci (SAHA)’s ffects to hum normal fibrob ast and cancer cell
cultur conditions. (A) Cellular doubling times of AG1522 and 549; (B) Cellular toxicity evaluated by
cell growth for three days in the presence SAHA; (C) Cellular toxicity evaluated by clonogenic ability
as plating efficiency; (D) Flow cytometry profiles after SAHA treatment for 24 h; and (E) Cell cycle
distribution after 24 h SAHA treatment. Error bars indicate standard error of the means. * marks mean
statistically significant differences compared to control (p < 0.05). All experiments were carried out at
least three times independently.
Cell cycle distribution after 24 h 2 µM SAHA treatment presented cell cycle arrest for both normal
cells and cancer cells in G1 phase (Figure 1D,E). G1 phase population increased from 50–60% to more
than 80%, with statistical significance (p < 0.05). S phase population was decreased from 30% to
5%, with statistical significance (p < 0.05). G2/M phase population remained the same. Therefore,
the slower cell division by SAHA treatment may arise from temporary cell division arrest, such as
activation of the cell cycle checkpoints but not permanent senescence.
2.2. Radiosensitization of Exponentially Growing Cancer Cells Exposed to γ-Rays, Protons and Clinical Grade
Carbon Ions
Two concentrations of SAHA (0.2 nd 2 µM) were used fo radiose sitization tests for the
exponentially growing A549 cells. It was found that 2 µM of SAHA pretreatment resulted in
statistically significant radiosensitization for γ-rays, proton SOBP (Spread out Bragg Peak), and
carbon ion SOBP (p < 0.05). In contrast, 0.2 µM of SAHA pretreatment induced statistically significant
radiosensitization with proton SOBP and carbon ion SOBP (p < 0.05) but not γ-rays (Figure 2A).
Although low concentrations of SAHA did not show any cell cycle differences from control (Figure 1D),
it showed similar sensitization effects to protons and carbon ion exposure for A549 lung cancer cell
line when compared to high concentrations of SAHA.
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Figure 2. SAHA induced radiosensitization for exponentially growing normal and cancer cells. (A) 
SAHA induced radiosensitization in exponentially growing A549 cancer cells; (B) No 
radiosensitization effect by SAHA treatment for exponentially growing AG1522 normal cells. Error 
bars indicate standard error of the means. * marks mean statistically significant differences compared 
to control (p < 0.05). All experiments were carried out at least three times independently. 
D10 values and Sensitization Enhancement Ratio (SER) values of each condition were 
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showed slightly stronger sensitization and slightly higher SER values. SAHA-induced 
radiosensitization was LET (Linear Energy Transfer) dependent. SAHA sensitized low LET 
radiation (γ-rays and protons) to a greater extent than high LET carbon ion radiation when 
sensitization effects were compared with SER. These results suggest that SAHA is expected to have 
positive synergistic effects with proton radiation, rather than high LET carbon ion exposure for 
cancer cell killing. On the other hand, at high doses (5 Gy), low or high concentration of SAHA 
treatment successfully sensitized cells to carbon ion irradiation (p < 0.05). 
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Figure 2. i ced ra i sensitization for exponentially growing normal and cancer cells. (A) SAHA
induced radiosensitization in exponentially growing A549 cancer cells; (B) No radiosensitization effect by
SAHA treatment for exponentially growing AG1522 normal cells. Error bars indicate standard error of the
means. * marks mean statistically significant differences compared to control (p < 0.05). All experiments
were carried out at least three times independently.
D10 values and Sensitization Enhancement Ratio (SER) values of each condition were summarized
in Table 1. Relative Bi logical Effectiveness (RBE) values for A549 obtained from the D10 values for each
condition howed RBE 1.24 for proton and 2.59 for carbon SOBP irradiation without SAHA treatment.
SER values 1.18 and 1.43 for γ-rays; 1.27 and 1.31 for protons; and 1.15 and 1.18 for carbon-ion (low and
high concentrations, respectively) (Table 1). High concentrations showed slightly stronger sensitization
and slightly higher SER values. SAHA-induced radiosensitization was LET (Li ear Energy Transfer)
dependent. SAHA sensitized low LET radiat on (γ-rays and pr tons) t a greater extent than high
LET carbon ion radiation when sensitization effects were compared with SER. These results suggest
that SAHA is expected to have positive synergistic effects with proton radiation, rather than high
LET carbon ion exposure for c ncer cell killing. On the other hand, at high doses (5 Gy), low or high
concentration of SAHA treatment successfully sensitized cells to carbon ion irradiation (p < 0.05).
Table 1. SAHA-induced radiosensitization in A549 and AG1522 cells in different qualities of radiation.
D10, Sensitization Enhancement Ratio (SER), and Relative Biological Effectiveness (RBE) values are
mean ± standard error of the means.
Irradiation Condition
A549 AG1522
D10 (Gy) SER RBE D10 (Gy) SER RBE
γ-rays Control 6.52 ± 0.33 NA NA 4.42 ± 0.13 NA NA
SAHA 0.2 µM 5.66 ± 0.44 1.18 ± 0.13 NA 4.30 ± 0.01 1.03 ± 0.05 NA
SAHA 2 µM 4.67 ± 0.16 1.43 ± 0.09 NA 4.08 ± 0.05 1.08 ± 0.03 NA
Proton SOBP Control 5.37 ± 0.24 NA 1.24 ± 0.07 3.55 ± 0.11 NA 1.25 ± 0.04
SAHA 0.2 µM 4.50 ± 0.01 1.27 ± 0.03 1.26 ± 0.09 3.16 ± 0.13 1.13 ± 0.05 1.38 ± 0.05
SAHA 2 µM 4.16 ± 0.32 1.31 ± 0.05 1.06 ± 0.09 3.15 ± 0.21 1.16 ± 0.09 1.33 ± 0.09
Carbon ion SOBP Control 2.56 ± 0.16 NA 2.59 ± 0.23 2.12 ± 0.04 NA 2.18 ± 0.31
SAHA 0.2 µM 2.24 ± 0.13 1.15 ± 0.16 2.43 ± 0.11 2.17 ± 0.25 1.05 ± 0.20 2.10 ± 0.32
SAHA 2 µM 2.18 ± 0.06 1.18 ± 0.05+ 2.12 ± 0.04 2.25 ± 0.08 0.95 ± 0.12 1.82 ± 0.06
NA: Not Applicable.
2.3. Minimum Radiosensitization Effect of SAHA for Exponentially Growing Normal Cells
In order to compare radiosensitization effects with cancer cells, normal human fibroblast AG1522
was used initially in exponentially log growth conditions. SAHA showed minimum radiosensitization
effects to this normal cell line when it was combined with γ-rays, protons, or carbon-ions (Figure 2B).
AG1522’s RBE values without SAHA treatment were 1.25 for protons and 2.18 for carbon ions.
SER values were 1.03 and 1.08 for γ-rays; 1.13 and 1.16 for protons; and 1.05 and 0.95 for carbon-ion (low
and high concentrations, respectively) (Table 1). SER values for normal cells were smaller than cancer
cells. Therefore, in log phase cells, SAHA’s radiosensitization is specific and stronger in cancer cells.
Int. J. Mol. Sci. 2018, 19, 496 6 of 17
2.4. G0/G1 Phase Cells and Potentially Lethal Damage Repair with Immediate or Delayed Subculture
In order to eliminate any cell cycle distribution effects to evaluate SAHA’s radionsensitization,
a further study was carried out in the synchronized cell population (Figure 3) and summarized to
Table 2. After more than 80% of normal cells were synchronized in G0/G1 phase by contact inhibition,
SAHA treatment was carried out 24 h prior to the irradiation. SAHA was kept in media for 24 h post
irradiation recovery period. When SAHA was absent, normal cells showed a clear increase of cell
survival with 24 h delayed subculture, compared to immediate subculture as potentially lethal damage
repair. The D10 values were increased from 4.31 Gy to 6.35 Gy by 24 h delayed subculture with γ-rays
(Table 2). Therefore, normal cells showed potentially lethal damage repair. Increased D10 values with
24 h delayed subculture was observed greater in γ-rays, intermediate with protons, and the lowest
with carbon ions. SAHA pretreatment did not affect cell survival for normal human fibroblast cells for
immediate subculture or delayed subculture (Figure 3A). Therefore, SAHA treatment did not sensitize
G0/G1 synchronized normal human fibroblasts and did not affect potentially lethal damage repair.
In order to investigate SAHA’s effect for further potentially lethal damage repair, SAHA treatment
was carried out with more than 75% of G1 synchronized A549 cells. Initially, potentially lethal damage
repair was confirmed in G1 phase A549 cells after γ-ray irradiation (Figure 3B) with significant
increase of cell survival with delayed subculture compared to immediate subculture (p < 0.05).
SAHA pretreatment sensitized cells, both immediate subcultured and delayed subcultured cells
to radiation in the presence of SAHA. Also, 24 h delayed subculture showed significant increased
cell survival compared to immediate subculture (Figure 3B) (p < 0.05). In order to clarify whether
SAHA sensitized A549 or affected potentially lethal damage repair, SAHA treatment was carried out
by adding SAHA immediately after irradiation and subculture 24 h later. Post irradiaiton treatment
of SAHA did not affect cell survival and did not inhibit potentially lethal damage repair. Therefore,
SAHA did not show any inhibition of potentially lethal damage repair in normal and cancer cells.
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Figure 3. SAHA induced radiosensitization for synchronized cell population and potentially lethal
damage recovery. (A) The effect of SAHA treatment for potentially lethal damage repair in contacted
inhibited G0/G1 phase AG1522 cells after γ-rays, proton, and carbon-ion exposure; (B) The effect
of SAHA treatment for potentially lethal damage repair in G1 phase synchronized A549 cancer cells
with γ-rays, proton, and car on-ion exposure; (C) DNA profil s for control and after synchronization.
Error bars indicate standard error of the means. * marks mean statistically significant diff nces
between immediat and d layed subculture (p < 0.05). All experiments were carried out at least three
times independently.
Table 2. Effect of delayed subculture and potentially lethal damage repair with SAHA treatment in
A549 and AG1522 cells for different qualities of radiation. D10 values are mean ± standard error of
the means.
AG1522, D10 (Gy) A549, D10 (Gy)
SAHA Treatment Started
Subculture Time after Irradiation
24 h Before 24 h Before After Irradiation
0 h 24 h 0 h 24 h 24 h
γ-rays Control 4.31 ± 0.41 6.35 ± 0.44 6.57 ± 0.37 8.43 ± 0.29 NA
SAHA 0.2 µM 4.49 ± 0.45 6.96 ± 0.36 6.01 ± 0.42 6.97 ± 1.13 8.77 ± 0.41
SAHA 2 µM 4.21 ± 0.73 7.02 ± 0.59 4.85 ± 0.95 6.15 ± 0.59 8.04 ± 0.24
Proton SOBP Control 3.90 ± 0.36 5.35 ± 1.30
SAHA 0.2 µM 3.78 ± 0.47 5.53 ± 1.90
SAHA 2 µM 2.81 ± 0.39 4.14 ± 0.89
Carbon ion SOBP Control 2.11 ± 0.75 3.09 ± 0.13
SAHA 0.2 µM 2.03 ± 0.25 2.93 ± 0.52
SAHA 2 µM 1.98 ± 0.06 2.57 ± 0.51
NA: Not Applicable.
2.5. DSB (Double Starand Break) Repair
As a molecular indicator for DNA double strand break and repair, radiation induced γ-H2AX
foci formation and disappearance were analyzed with SAHA treatment. An initial number of foci
at 30 or 60 min after radiation exposure di not change with or without SAHA treatment with
γ-ray exposu e and carbon ion exposure for AG1522 cells. However, with roton exposure, 2 µM
SAHA reatment significantly increased foci number (Figure 4A). Foci number decreas d w th time
after radiation exposure. SAHA treatment reduced the rate of foci disappearance. Then, 24 h after
radiation exposure, approximately two times more foci were observed with high concentration of
SAHA treatment following treatment with γ-rays without statistical significance and three times
for carbon-ion exposure with statistical significance (p < 0.05) (Figure 4A) but no differences for
proton exposure.
As a direct indicator for DNA double strand break repair, low voltage constant field gel
electrophoresis was carried out to confirm SAHA’s effect in DNA double strand break formation
and rep ir wi h A549 cells. SAHA treatm nt slightly increas d initial DNA double strand break
formatio after γ-rays and proton exposure, which was evaluated as migrated DNA from well with
statistical significance (p < 0.05) (Figure 4B). However, differences in residual DNA double strand
breaks between each sample were not detected at 2 h after either γ-rays or proton irradiation of 40 Gy
in A549 cells (Figure 4B).
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Figure 4. SAHA induced radiosensitization in DNA damage and repair. (A) γ-H2AX foci kinetics
in AG1522 cell lines after 1 Gy of different radiation qualities; (B) Constant field gel electrophoresis
analysis in A549 after 40 Gy of radi tion; (C) Chromosome ab rrations after 4 Gy of γ-r y irradiation
to AG1522. Error bars i icate standard error of the means. All expe im nts were carried out at least
three times independently. * marks indicate statistically significant differences (p < 0.05).
2.6. Chromosomal Aberrations
SAHA treatment did not affe t radiation induced ch omosomal aber ati n formation (dicentric
and ring chromosome formation) i n rmal human fibroblasts after 4 Gy of γ-ray exposure (Figure 4C).
Human normal fibroblast cells were not sensitized for cell killing and chromosomal aberration
formation with SAHA treatment combined with γ-rays.
2.7. Rad51 and RPA (Replication Protein A) Focus Formation
SAHA’s effect on homologous recombination repair was analyzed by Rad51 and RPA foci
formation at 3 and 5 h after 1 Gy of γ-ray or proton beam radiation in cancer cell line. SAHA treatment
suppressed Rad51 and RPA foci formation in control and γ-ray and proton beams irradiated samples,
and it was significant for 2 µM of SAHA (Figure 5A,B).
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3. Discussion
Although multiple radiosensitizers were investigated and proposed for clinical uses, there are
no clinically relevant radiosensitizers yet available. One of the major problems is non-selective
radios ns tiza on between cancer cells and normal cells. In order to overcome this issue, several
strategies including targeting drug delivery sys ems have been invest gate [27]. Even SAHA has been
investigated for targeted drug delivery system to improve efficacy [28–30]. A potential solution is to
search for drugs that can selectively sensitize cancer cells to ionizing radiation, while neglecting normal
cells. Significantly, anti-tumor drugs with the selective radio-sensitizing properties are most desirable
because of its double synergistic effects; anti-tumor cell killing and tumor-selective radio-sensitization.
SAHA is an anti-tumor drug and it is known that the cytotoxic effects are limited to transformed and
cancerous cells [31]. Many reports showed SAHA induced radio-sensitization in cancer cells with
photon and hadron radiation [17–20,32]. A prior study showed SAHA’s selective radi sensitization to
cancer c lls (sarcoma, glioblastom , squamous cell carcinoma) with photon irradiation [23]. Our report
expands this and is the first investigation to inclu e a normal human fibroblast cell line and a human
lung cancer cell line with photon, proton and carbon ion radiation together for SAHA’s selective
radiosensitization (Figures 2 and 3).
Hadron radiation more efficiently delivers dose in tumor volume when compared to photon
radiation. For current clinically available hadron radiation, proton radiation surpasses carbon ion
radiation for dose distribution [33]. The majority of carbon ions are fragmented by the collision with
targets. As a result, the distal end of carbon ion irradiation has more dose deposition than proton
irradiation [34]. T is dose deposition at the distal end is important for the cancer treatment regarding
evaluating patient’s sec ndary cancer risk and irreversible late effects ch a radiation-induc lung
fibrosis [33,35].
SAHA’s cancer specific radiosensitization has unclear mechanisms. A series of publications
have shown that suppression of homologous recombination repair by HDACi treatment, including
SAHA and homologous recombination associated RAD50 and MRE11 suppression, were observed
in cancer cells only [10,11,14,32]. A recent study observed SAHA and cisplatin treated cancer cells
showed hypersensitivity to radiation [32]. Both low and high concentrations of SAHA treatment
successfully sensitized exponentially growing cancer cells (Figure 2A). S phase cells were significantly
decreased and G1 arrest was seen in both ll lines fter treatment with 2 µM SAHA, but not with
low concentration 0.2 µM SAHA (Figure 1D,E). This may imply at low and high c ncentrations of
SAHA’s cell sensitizing mechanism may be different from imple cell cycle distribution effects, such as
accumulation of cell population into radiosensitive G1 phase [36,37]. It is known that HDACi increases
p53 acetylation and activates cell cycle checkpoints by p21, resulting in cell arrest in G1 or G2/M [38].
SAHA induced arrest at G1 phase in AG1522 and A549, which have a p53 wild type status, might be
the result of proper p53 function. Although we have also observed the reduction of Rad51 and RPA
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foci (Figure 5A,B), suppression of homologous recombination repair cannot explain the mechanism of
neither cancer specific radiosensitization nor radiosensitization of G1 phase synchronized A549 cells.
Other reports showed suppression of non-homologous end joining repair-associated proteins
including Ku86, Ku70 and DNA-PKcs with HDACi [15,39,40]. HDACi induced acetylation of
Ku70 decreases its binding activity to DNA, resulting in impaired double strand break repair [16].
Reduction of non-homologous end joining repair should increase radiosensitivity in not only G1
phase, but also all cell cycle phases. Often, suppression of non-homologous end joining repair leads to
suppression of potentially lethal damage repair [41]. We observed sensitization in G1 phase cancer
cells with SAHA treatment but potentially lethal damage repair was intact with SAHA treatment
(Figure 3). Therefore, the major mechanisms of radio-sensitization were not fully explained by simple
DNA repair protein inhibitory model, such as suppression of Ku86 or Rad51. Furthermore, SAHA
treatment extends the longevity of phosphorylation of H2AX signal [4]. Strikingly, we were able to
observe this in normal human fibroblasts (Figure 4A), which were minimally sensitized by SAHA.
Because we did not observe clear DNA double strand break repair reduction in constant field gel
electrophoresis (Figure 4B), the ultimate mechanisms of SAHA-induced radiosensitization may be
different from DNA double strand break repair.
HDACi is an epigenetic drug and has a wide range of action. Morphological changes of tumor
cells, including chromatin texture, are one of the important criteria for cancer diagnosis. For successful
repair of double strand break, chromatin needs to be fully decondensed for access of repair proteins to
the site of DNA damage and the chromatin needs to be fully recondensed once the repair is completed,
which is an essential process for accurate DNA repair [42]. The difference of chromatin structure in
cancer cells may increase the accessibility of HDACi to the histone and may interfere restoration of
chromatin once the repair is completed [43–45].
4. Materials and Methods
4.1. Cell Culture
A549, a lung small cell carcinoma and AG1522, a normal human fibroblast cell line, were kindly
supplied from Dr. Joel Bedford at Colorado State University (Fort Collins, CO, USA). Cells were
cultured in MEM-alpha (Gibco, Indianapolis, IN, USA) supplemented with 10% heat inactivated fetal
bovine serum (Sigma, St Louis, MO, USA) for cancer cells and 15% for normal cells and 1% penicillin,
streptomycin and Fungizone solution (anti-anti; Invitrogen Life Technologies, Carlsbad, CA, USA),
and they were maintained at 37 ◦C in a humidified atmosphere of 5% CO2 in air. SAHA was purchased
from Sigma. Then, 200 µM stock solution was prepared in dimethylsulfoxide (DMSO) and diluted to
0.2 µM and 2 µM of working solution in MEM-alpha. SAHA treatment was carried out for 24 h.
4.2. Cell Cycle Synchronization
For normal human fibroblasts, cells were synchronized in G0/G1 phase by contact inhibition.
After cells reached into confluency, we changed media and waited for 2 days before experiment
to ensure contact inhibition. For cancer cells, which cannot be synchronized by contact inhibition,
cell culture medium was changed into isoleucine depleted MEM-media (Gibco) supplemented with
5% three times dialyzed serum and 1% penicillin, streptomycin and Fungizone solution as previously
described [46,47]. Cells were incubated in this media for 24 h to synchronize them into G1 phase.
Cell cycle synchronization was confirmed with FACSCalibur Flow Cytometer (BD Biosciences, Franklin
Lakes, NJ, USA).
4.3. Irradiation
Cells were irradiated with either γ radiation, spread out Bragg peak (SOBP) of protons,
or carbon-ions at room temperature. For γ-ray irradiation, a J. L. Shepherd Model Mark I-68 nominal
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6000 Ci Cs-137 sealed source (J. L. Shepherd, Carlsbad, CA, USA) at the Colorado State University was
used with a dose rate of 2.5 Gy per min.
For proton beam irradiation, 200 MeV proton beams were generated by the synchrotron at the
Proton Medical Research Center (PMRC) of University of Tsukuba (Ibaraki, Japan). Proton dosimetry
was measured as previously described [48,49]. The estimated energy spread and dose-average
LET values at the middle of the 6-cm SOBP were 0–60 MeV and 2.2 keV/µm, respectively [49,50].
We classified middle of SOBP protons as low LET radiation. Proton beam irradiations were performed
at the middle of the 6 cm SOBP with a dose rate of approximately 3 Gy/min.
Carbon-ion experiments were carried out using the heavy ion medical accelerator (HIMAC) at
National Institute of Radiological Sciences (Chiba, Japan). Carbon ions were accelerated at 290 MeV/n
of initial energy and spread out with a ridge filter for 6 cm width of SOBP. The monolayer culture in
flasks was irradiated at the center within the SOBP at a distance of 119 mm from the entrance. The dose
averaged LET of the carbon ions at the middle of 6 cm SOBP is about 50 keV/µm at the distance of
119 mm from the entrance with a dose rate of 1 Gy/min [51,52]. We classified middle of SOBP carbon
ions as high LET radiation.
4.4. Cellular Toxicity and Cell Cycle Analysis
Firstly, 5000 cells were plated onto 6 well plates and cell number was counted by Coulter Counter
Z1 (Beckman Coulter, Indianapolis, IN, USA) every 24 h for 5 days. Cell doubling time was calculated
by using GraphPad Prism 6 with exponential growing equation from exponentially growing cell stage.
Cellular toxicity was determined by growth inhibition in the presence of SAHA. Then, 7000 cells were
exposed to 0, 0.2, 2, or 4 µM of SAHA for 3 days. Cell numbers of each condition were counted by
Coulter Counter Z1.
For the clonogenicity test, after 24 h treatment of SAHA, cells were trypsinized to obtain single cell
suspension. Then, 300–3000 cells were plated onto dishes to form colonies for 7–14 days. Dishes were
fixed with ethanol and stained with 0.1% crystal violet. Macroscopic colonies containing more than
50 cells were marked as a survivor [53]. Plating efficiency (%) was calculated by observed colony
number divided by plated single cell number.
Cell cycle analysis was carried out as previously described [54]. Briefly, after cells were exposed
to SAHA for 24 h, cells were fixed in 70% ethanol and DNA was stained with Propidium iodide and
followed by RNase treatment. Flow cytometry analysis was carried out with FACSCalibur and cell
cycle distribution was determined with MODFIT LT version 3 software (Verity Software, Topsham,
ME, USA) analysis.
4.5. Cell Survival Curves and RBE Analysis
After irradiation, cells were trypsinized and plated to form approximately 30–300 colonies.
Cell survival curves were drawn from cell survival fraction by Graphpad Prism 6 (GraphPad, La Jolla,
CA, USA) with linear quadratic regression model. D10 values (radiation dose to achieve 10% cell
survival) were obtained. Relative biological effectiveness (RBE) and sensitization enhancement ratio
(SER) values were calculated from D10 values. RBE values were calculated from the required γ-ray
dose to kill 90% cells (D10, γ) divided by a testing radiation dose to kill 90% of cells (D10, testing radiation).
RBE values more than 1 mean the testing radiation efficiently kills cells and has higher biological
effectiveness compared to γ-rays. SER values were calculated from the dose required to kill 90% cells
without sensitizer (D10, control) divided by a dose to kill 90% cells with testing sensitizer (D10, sensitizer).
SER values higher than 1 mean testing sensitizer synergistically kills cells with radiation.
4.6. Potentially Lethal Damage Repair Analysis with Immediate or Delayed Subculture
Potentially lethal damage repair is the recovery of radiation damage in the resting phase [55,56].
In order to determine whether SAHA in the media affects potentially lethal damage repair, G0/G1
synchronized cells were cultured with SAHA for 24 h before irradiation. After irradiation, they were
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immediately subcultured for colony formation to determine radiosensitivity without potentially lethal
damage repair. On the other hand, after irradiation, cells were kept in the same media with SAHA for
additional 24 h before trypsinization for colony formation (delayed subculture) to observe increased
survival with potentially lethal damage repair. For the last group, 24 h SAHA treatment was started
just after irradiation by adding SAHA to cell culture media and radiosensitivity was determined
by colony formation assay after potentially lethal damage repair. Experimental procedures were
summarized in Figure 6. Potentially lethal damage repair was analyzed by increased survival with
greater D10 values obtained by cell survival curves.
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Figure 6. Potentially lethal damage repair analysis with immediate and delayed subculture.
Synchronized cells were irradiated with or without SAHA treatment. After irradiation, cells were
immediately subcultured for colony formation or delayed subculture after 24 h incubation in the
presence of SAHA.
4.7. Immunostaining and DNA Damage Response Analysis
γ-H2AX foci were analyzed for the contact inhibited G0/G1 AG1522 cells because S phase cells
have a high background number of foci and γ-H2AX analysis is affected by cell cycle distribution.
Rad51 and RPA foci were analyzed for the exponentially growing A549 cells. Cells were fixed in 4%
paraformaldehyde for 15 min and treated for 5 min in 0.2% Triton X-100 (Sigma, St Louis, MO, USA) in
PBS at room temperature, and blocked overnight at 4 ◦C in 10% goat serum solution. Immunostaining
was carried out with mouse monoclonal primary antibody against γ-H2AX (Millipore, Billerica, MA,
USA), Rad51 and RPA (Abram, Cambridge, MA, USA) and Alexa Fluor488-conjugated goat anti-mouse
(Invitrogen Life Technologies). Cells were mounted with ProLong Gold Antifade Reagent with DAPI
(Invitrogen Life Technologies). Then, 0.7 to 1.0-micron thick z-stack fluorescence images were captured
using a Zeiss Axioskop motorized z-stage fluorescent microscope (Zeiss, Jena, Germany) equipped
with CoolSNAP HQ2 (Photometrics, Tucson, AZ, USA) or Biozero BZ-8000 (Keyence, Tokyo, Japan).
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Extended focus images were obtained by Metamorph software (Molecular Devices, Sunnyvale, CA,
USA). Three independent experiments were performed. At least 50 cells were analyzed for each
experiment. Manual and Foci counter software-based counting was performed for foci analysis
(http://focicounter.sourceforge.net/index.html).
Foci analysis shows the presence of repair proteins and phosphorylated form of histone proteins
and indirect measurement of DNA damage and repair. In order to quantify actual DNA double
strand break and repair, DNA double strand break was measured by the low voltage constant field
gel electrophoresis method. This assay requires much higher doses compared to γ-H2AX foci assay.
First, 250,000 cells were embedded in 0.5% low melting point agarose. After lysis with proteinase K
and RNase treatment, electrophoresis was carried out in 0.5x TBE buffer in 0.6% agarose gel at room
temperature in a constant field of 0.6 V/cm for 40 h. Gels were stained with Ethidium Bromide and
the intensities of DNA which were retained in the plug and released into the lane were measured by
Bio-rad ChemiDoc imager with Image Lab Software (Bio-Rad, Hercules, CA, USA). The fraction of
DNA released was calculated from the amount of DNA in the plug and lane.
4.8. Chromosome Aberration Analysis
Contact inhibited G0/G1 phase AG1522 cells were pretreated with SAHA for 24 h before γ-ray
irradiation. Immediately after irradiation, cells were trypsinized and replated. The first post irradiation
metaphase cells were harvested with 0.1 µg/mL Colcemid (Invitrogen Life Technologies) treatment
and prepared as a standard method [57]. Samples were treated in 75 mM KCl solution for 20 min at
37 ◦C and fixed in 3:1 (methanol: acetic acid) Carnoy fixation solution three times. Metaphase spreads
were stained with 5% Giemsa solution, and the chromosome aberrations (dicentric chromosomes and
ring chromosomes) were analyzed. A minimum of 100 metaphase cells was analyzed for each data
point for at least two independent experiments.
4.9. Statistics
All experiments were carried out at least three times and error bars indicate standard error
of the means. Data was analyzed using Prism 6 software for t-test and one-way ANOVA analysis.
p-Values < 0.05 were categorized as significant differences.
5. Conclusions
Even though the molecular mechanisms of radiosensitization in cancer cells remain unclear,
SAHA successfully sensitizes cells to radiation, even with high LET radiation. Importantly, we proved
that SAHA selectively sensitized cancer cells to photon and hadron radiation. SAHA treatment did
not affect potentially lethal damage repair. Potentially lethal damage repair is more important for
low LET radiation, such as γ-rays and proton. This may be due to spatially distant DSBs, unable to
interact or form lesions. On the other hand, high LET increases clusters of DSBs that contain the ability
to form irreparable lesion. Based on the radiation dose control, enhancement ratio, and potential
lower side effects for normal cells, SAHA treatment may be the most effective when combined with
protons. Although our results show promising evidence, future studies utilizing other cell lines will be
important to prove our hypothesis and strengthen the evidence that SAHA treatment can selectively
kill cancer cells when combined with radiation.
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